Lai LY - Search Results

1

Risk of Metabolic and Cardiovascular Adverse Events With Abiraterone or Enzalutamide Among Men With Advanced Prostate Cancer.

Lai LY, Oerline MK, Caram MEV, Tsao PA, Kaufman SR, Hollenbeck BK, Shahinian VB. Lai LY, et al. J Natl Cancer Inst. 2022 Aug 8;114(8):1127-1134. doi: 10.1093/jnci/djac081. J Natl Cancer Inst. 2022. PMID: 35417024 Free PMC article.

2

Understanding Active Surveillance for Prostate Cancer.

Lai LY, Shahinian VB, Oerline MK, Kaufman SR, Skolarus TA, Caram MEV, Hollenbeck BK. Lai LY, et al. JCO Oncol Pract. 2021 Nov;17(11):e1678-e1687. doi: 10.1200/OP.20.00929. Epub 2021 Apr 8. JCO Oncol Pract. 2021. PMID: 33830822 Free PMC article.

3

Impact of Advanced Practice Provider Integration into Multispecialty Group Practices on Outcomes Following Major Surgery.

Lai LY, Kaufman SR, Modi PK, Ellimoottil C, Oerline M, Caram MEV, Hollenbeck BK, Shahinian VB. Lai LY, et al. Surg Innov. 2022 Feb;29(1):111-117. doi: 10.1177/15533506211013150. Epub 2021 Apr 24. Surg Innov. 2022. PMID: 33896274 Free PMC article.

4

Promotional Payments to Medical Oncologists and Urologists and Prescriptions for Abiraterone and Enzalutamide.

Lai LY, Oerline MK, Kaufman SR, Herrel LA, Skolarus TA, Dusetzina SB, Ellimoottil C, Shahinian VB, Hollenbeck BK, Caram MEV. Lai LY, et al. Urology. 2022 Mar;161:50-58. doi: 10.1016/j.urology.2021.10.042. Epub 2021 Dec 1. Urology. 2022. PMID: 34861316 Free PMC article.

5

AUTHOR REPLY.

Lai LY, Caram MEV, Shahinian VB, Hollenbeck BK. Lai LY, et al. Urology. 2022 Mar;161:58. doi: 10.1016/j.urology.2021.10.045. Urology. 2022. PMID: 35307078 No abstract available.

6

Physician Dispensing Among Urology Practices and the Use of Abiraterone or Enzalutamide for Men With Advanced Prostate Cancer.

Lai LY, Kaufman SR, Oerline MK, Caram MEV, Maganty A, Hollenbeck BK, Shahinian VB. Lai LY, et al. JNCI Cancer Spectr. 2022 Mar 2;6(2):pkac023. doi: 10.1093/jncics/pkac023. JNCI Cancer Spectr. 2022. PMID: 35603854 Free PMC article.

7

Implications of the Merit-Based Incentive Payment System for Urology Practices.

Maganty A, Hollenbeck BK, Kaufman SR, Oerline MK, Lai LY, Caram MEV, Shahinian VB. Maganty A, et al. Among authors: lai ly. Urology. 2022 Nov;169:84-91. doi: 10.1016/j.urology.2022.05.052. Epub 2022 Aug 3. Urology. 2022. PMID: 35932872 Free PMC article.

8

Effects of In-office Dispensing by Single-specialty Urology Practices on Management of Advanced Prostate Cancer.

Lai LY, Kaufman SR, Oerline M, Caram MEV, Maganty A, Shahinian VB, Hollenbeck BK. Lai LY, et al. Urol Pract. 2023 May;10(3):230-235. doi: 10.1097/UPJ.0000000000000390. Epub 2023 Jan 30. Urol Pract. 2023. PMID: 37103497

9

Commercial Prices for Prostatectomy and Treatment among Younger, Privately Insured Men with Prostate Cancer.

Lai LY, Kaufman SR, Oerline MK, Ryan AM, Ellimoottil C, Caram MEV, Shahinian VB, Hollenbeck BK. Lai LY, et al. Urol Pract. 2021 Nov;8(6):611-618. doi: 10.1097/UPJ.0000000000000252. Epub 2021 Aug 18. Urol Pract. 2021. PMID: 37145503

10

Practice Competition and Treatment of Newly Diagnosed Prostate Cancer.

Maganty A, Hollenbeck BK, Kaufman SR, Oerline MK, Lai LY, Caram MEV, Shahinian VB. Maganty A, et al. Among authors: lai ly. Urology. 2023 Jul;177:95-102. doi: 10.1016/j.urology.2023.04.022. Epub 2023 May 3. Urology. 2023. PMID: 37146728

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

154 results

Search Page